Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Napp Pharmaceuticals Limited
• Treatments: Acetaminophen; Buprenorphine; Codeine

Criteria

Inclusion Criteria:

• Either sex aged 65 or above

• Diagnosis of OA of the hip and/or knee

• Severe pain requiring step two medication

• Taking maximum dose of paracetamol

Exclusion Criteria:

• Painful disease of the joints other than OA

• Contraindication to buprenorphine, other opioids, patch adhesives or nonsteroidal anti-inflammatory agents (NSAIDS)

• Subjects taking cyclooxygenase (COX) II selective inhibitors